New data presented at the 2017 Leipzig Interventional Course (LINC) have demonstrated strong efficacy and consistent outcomes for Medtronic’s IN.PACT Admiral drug-coated balloon across multiple patient populations. The data represent real-world outcomes from regional cohorts of the IN.PACT Global Study in Asia and Belgium.
Donghoon Choi from the division of cardiology at Severance Cardiovascular Hospital, Seoul, South Korea, presented one-year results from the Asian subset of the IN.PACT Global Study, including data from 114 patients at six sites in South Korea and Singapore.
In this subset analysis, the low clinically-driven target lesion revascularisation at one year (3.8%) was consistent with the results in the complete cohort of 1,406 patients in the IN.PACT Global Study (7.5%). Results of the primary safety endpoint in the Asian cohort were also consistent with results from the full Global Study cohort, with 96.2% of patients achieving positive outcomes.
In a separate presentation of results from the IN.PACT Global Study, Koen Deloose from the vascular surgery unit at AZ Sint Blasius, Dendermonde, Belgium, presented data on 305 patients from seven sites in Belgium. Belgium was the first country to enrol patients in the study and remains the largest enrolling country. At one year, patients experienced positive outcomes based on both efficacy and safety measures, consistent with overall findings from the IN.PACT Global Study.
In this patient subset, the low clinically-driven target lesion revascularisation at one year (7.6%) was also consistent with the results in the complete cohort of patients in the IN.PACT Global Study (7.5%). Results of the primary safety endpoint in the Belgium cohort were also consistent with results from the full study, with 90.6% of patients achieving positive outcomes.
